Latest Competition News

Bass Oil is set to ramp up Indonesian production by drilling the Bunian 6 well, targeting a tripling of output to 750 barrels per day by mid-2026 amid elevated oil prices.

BlinkLab has secured A$17.5 million through an oversubscribed placement to fuel regulatory trials and commercial launch of its AI-driven autism and ADHD diagnostic tools.

Nutritional Growth Solutions has appointed director Manik Pujara as interim CEO and CFO, replacing Andrew Grover who remains as nonexecutive chair. This leadership shuffle coincides with ongoing exploration of corporate opportunities.

AMP Limited's first quarter of 2026 saw Platforms net cashflows jump 45% to $1.1 billion, alongside improved outflows in Superannuation & Investments and a $150 million share buyback commencement. The bank's GO deposits also surged, signaling momentum despite market headwinds.

PPK Group’s majority-owned PowerPlus Energy has won a $2.3 million ARENA grant to scale up its Melbourne battery pack manufacturing, aiming to triple production capacity to 150 MWh annually over two years.

Fletcher Building posted a mixed quarterly volume update for Q3 FY26, with gains in light building products and distribution offset by weakness in heavy materials. The recent Middle East conflict adds new supply chain and cost pressures, complicating the outlook.

Contact Energy’s March 2026 report reveals a solid rise in electricity and gas sales alongside a notable decline in generation costs, driven by increased renewable output and strong hydro storage levels.

Desert Metals Limited has launched a fully underwritten entitlement offer to raise approximately $325,000 through new options, aiming to fund ongoing exploration at its gold prospects in Côte d’Ivoire.

Ovanti Limited has raised $5.27 million through a discounted placement, aiming to accelerate its global Buy Now Pay Later platform and Super App development with AI integration and merchant expansion.

Charger Metals has confirmed significant extensions to spodumene mineralisation at its Medcalf project, with drilling pushing lithium-bearing pegmatites to 600-700m depth and along strike. The company anticipates a substantial resource upgrade following assay results due in the coming weeks.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.